CD19 and congenital rubella syndrome: Both could be managed with supportive care, anti-IL-6 receptor monoclonal antibody and glucocorticoids.[21] Patients with a high disease burden (≥5% bone marrow blasts or extramedullary disease) had a greater incidence of CRS and neurotoxic events.[21] The bone marrow and skin tissues achieved CR, which indicated a powerful potency for the CD19 CART-cell therapy for systemic disease control.